Daniel Muehl - Clovis Oncology Executive

Summary

CLVSDelisted Stock

USD 0.09 0.02 24.00%

Executive

Mr. Daniel W. Muehl is Executive Vice President of Finance, Principal Accounting Officer and Principal Financial Officer of the Company since 2019.

Age	59
Tenure	5 years
Phone	303 625 5000
Web	https://www.clovisoncology.com

Muehl was appointed our Principal Accounting Officer and Principal Financial Officer in March 2016 and has served as our Executive Vice President of Finance since February 2019 and, prior to that, as our Senior Vice President of Finance from September 2016 and Vice President of Finance since 2015. Previously, Mr. Muehl was the Chief Financial Officer of biotechnology company Somalogic, Inc. from 2014 to 2015 and prior to that the Chief Financial Officer of bioindustrial company OPX Biotechnologies, Inc. from 2010 to 2014. He earned a BS degree in accounting from the University of Massachusetts—Amherst and received his Certified Public Accountant certificate in 1990.

Clovis Oncology Management Efficiency

The company has return on total asset (ROA) of (0.3018) % which means that it has lost $0.3018 on every $100 spent on assets. This is way below average. Clovis Oncology's management efficiency ratios could be used to measure how well Clovis Oncology manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Clovis Oncology to Peers

Clovis Oncology currently holds 436.77 M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has a current ratio of 1.15, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Clovis Oncology's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			EXECUTIVE Age
	Esq III	Xponential Fitness	43
	David Sweet	Griffon	N/A
	Danyal Ali	Xponential Fitness	N/A
	Jura Mazuran	Xponential Fitness	N/A
	Lorraine Lang	Arq Inc	N/A
	Shelette Gustafson	Jacobs Solutions	59
	Clay Smith	Arq Inc	N/A
	Madhuri Andrews	Jacobs Solutions	57
	Venkatesh Nathamuni	Jacobs Solutions	N/A
	Mark Stach	Balchem	62
	Jonathan CFA	Jacobs Solutions	N/A
	Garrett Chandler	Arq Inc	N/A
	Frederic Boned	Balchem	46
	Jeremy Williamson	Arq Inc	43
	Robert Duff	Jacobs Solutions	65
	Joseph Wong	Arq Inc	63
	Jonathan Griffin	Balchem	48
	Martin Reid	Balchem	56
	Stephen Arnette	Jacobs Solutions	56
	Rhonda Anderson	Primoris Services	N/A
	Scot Kathmann	Primoris Services	N/A

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people. Clovis Oncology (CLVS) is traded on NASDAQ Exchange in USA and employs 413 people.

Management Performance

Return On Asset

-0.3

Clovis Oncology Leadership Team

Elected by the shareholders, the Clovis Oncology's board of directors comprises two types of representatives: Clovis Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clovis. The board's role is to monitor Clovis Oncology's management team and ensure that shareholders' interests are well served. Clovis Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clovis Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Anna Sussman, VP Relations
	Patrick MA, CEO, CoFounder
	BSc BSc, Exec Officer
	Paul Gross, Executive Vice President Chief Compliance Officer, General Counsel
	Ann Bozeman, Executive Vice President of Human Resources
	Thomas BSc, Ex Officer
	Daniel Muehl, Principal Financial Officer, Principal Accounting Officer

Clovis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clovis Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-0.3
	Profit Margin	(1.89) %
	Operating Margin	(1.55) %
	Current Valuation	651.32 M
	Shares Outstanding	144.96 M
	Shares Owned By Insiders	1.43 %
	Shares Owned By Institutions	25.89 %
	Number Of Shares Shorted	28.49 M
	Price To Earning	(8.65) X
	Price To Sales	0.11 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Clovis Stock

If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC